Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Enrolling By Invitation
18 years - 99 years
All
Phase
1
7 participants needed
1 Location
Brief description of study
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: solid tumors
-
Age: 18 years - 99 years
-
Gender: All
Male or female age 18 or older Measurable tumor
Updated on
04 Aug 2024.
Study ID: 849870
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
